Background. We recently published and validated the new serum creatinine (Scr)-based full-age-spectrum equation (FAS crea ) for estimating the glomerular filtration rate (GFR) for healthy and kidney-diseased subjects of all ages. The equation was based on the concept of normalized Scr and shows equivalent to superior prediction performance to the currently recommended equations for children, adolescents, adults and older adults. 
I N T R O D U C T I O N
Serum creatinine (Scr)-based estimating glomerular filtration rate (eGFR) equations are commonly used and reported when Scr is measured. Despite the worldwide acceptance of isotope dilution mass spectrometry (IDMS)-standardized Scr assays, Scr-based eGFR equations are still relatively imprecise [1] . Also, different equations are proposed for children, adults and older adults as most equations lack continuity and accuracy across the full age spectrum.
We recently published a Scr-based full-age-spectrum (FAS crea ) equation [2] that has been validated in a large number of healthy and kidney-diseased white individuals (n ¼ 6870) including 735 children, 4371 adults and 1764 older adults against measured GFR (mGFR) and using IDMS-equivalent Scr. The FAS crea equation showed improved validity and continuity across the full age spectrum and was less biased and more accurate than the currently recommended Scr-based eGFR equations.
The FAS equation is based on three fundamental assumptions:
• The average GFR for healthy populations (children, adolescents and young adults) is equal to a value of 107.3 mL/ min/1.73 m 2 after kidney function matures (around 2 years of age) until the age of 40 years. This assumption is also supported by the results of a recent meta-analysis in living kidney donors [3] .
• The age decline of GFR begins at around 40 years.
• GFR and population-normalized Scr (Scr/Q crea ) are inversely related (Q crea being the mean or median Scr concentration of the corresponding age-/sex-matched healthy population).
These three assumptions have led to the construction of the simple age-knotted FAS crea equation, which takes the form [2] : The equation is simple and intuitive and can be easily explained: when Scr/Q crea deviates from '1', the eGFR will deviate from the average value of 107.3 mL/min/1.73 m 2 . Scr/Q crea , for every healthy age-/sex-matched population, is normally distributed (Gaussian distribution) around the mean of '1' (a consequence of the definition of Q crea ). It has been shown that the 2.5th percentile (Pct) ¼ 0.67 and the 97.5th Pct ¼ 1.33, or, equivalently, the standard deviation (SD) is 0.1683 [2] .
Serum cystatin C (ScysC) is considered to be a potential alternative to Scr for estimating GFR [4] , especially since a certified reference cystatin C material became available in 2010, allowing standardization of ScysC assays [5] .
In this article, we demonstrate that the last assumption (that GFR is inversely related to the normalized Scr biomarker) also applies to ScysC, if properly normalized. We show that the FAS crea equation can be transformed into a ScysC-based FAS equation (FAS cysC ) and a combined Scr-/ScysC-based FAS equation (FAS combi ) , by simply replacing the normalized Scr (Scr/Q crea ) by ScysC/Q cysC or by the combination of Scr/Q crea and ScysC/Q cysC [i.e. the (weighted) average of Scr/Q crea and ScysC/Q cysC ], where Q cysC is the normalization factor for ScysC.
In the first part of this study, we give a rationale for choosing the normalization factor Q cysC for ScysC. Next, we validate the FAS cysC and FAS combi equation against mGFR and compare the performance of these equations with the currently recommended and most used eGFR equations (Schwartz cysC [6] , Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI cysC ) [4] , Caucasian Asian Paediatric Adult Cohort equation (CAPA) [7] , combined CKD-EPI combi [4] and BIS2 [8] ). Finally, we evaluate the performance of all FAS equations (by varying the weighting factors for the normalized biomarkers) in all age groups.
M A T E R I A L S A N D M E T H O D S

Overview of study design and participants
We collected data from 11 cohorts, forming a representative sample of the general population and renal disease patients. For the same six cohorts (Saint-Etienne, Tromsø, Rochester and Minnesota for adults; Kent and Berlin for older adults [2] ) that were used for the validation of the FAS crea equation, we additionally collected the ScysC results. The other cohorts used in the previous validation did not have ScysC data available, and, therefore, we collected data of new cohorts. For children, adolescents and young adults (<21 years), one cohort came from the University Hospital in Leuven (n ¼ 114), and one from Lyon (n ¼ 695). Both cohorts contained children and adolescents with established renal pathologies. The data from Leuven contained single-time point measurements per child and the data from Lyon (n ¼ 695) were from 259 children with serial measurements over a period of several years, but we used the first measurement only. We further collected data from a cohort of healthy and renal disease adults from Paris (n ¼ 603), from Lyon (n ¼ 598) and from the Chronic Renal Insufficiency Cohort (CRIC; n ¼ 3939) [9] , which we restricted to whites only (n ¼ 1824) and to the first visit where all required variables were available (n ¼ 674). All datasets were centralized by the first author for data analysis. This retrospective non-interventional study was approved by the Institutional Ethical Board of the University Hospital of Leuven, Belgium.
In total, we collected data on mGFR, Scr, ScysC, age, gender, height and weight for n ¼ 6132 participants (n ¼ 368 children aged between 1 and 18 years; n ¼ 4295 adults aged between 18 and 70 years and n ¼ 1469 older adults aged !70 years).
We further used a separate cohort (n ¼ 1333) from the Berlin Initiative Study [8] of apparently healthy older subjects to study the age dependency of the ScysC distribution. This cohort was obtained from 2069 subjects (2069 baseline samples and 1693 follow-up samples) aged >70 years (Berlin residents), which we reduced to a subset of 1333 individuals who were defined as apparently healthy; i.e. no history of myocardial infarction, no history of stroke, not on dialysis, not deceased between first and second follow-up study visit, no albuminuria (ACR <30 mg/g), arterial blood pressure <160/90 mmHg.
Methods
The new FAS equation(s). The form of the FAS crea equation was maintained, but Scr/Q crea is replaced by S cysC /Q cysC :
By extending the same concept, we used the weighted average of the two normalized biomarkers Scr/Q crea and ScysC/ Q cysC , leading to the general form of:
The coefficient 'a' in the denominator may be considered as a weighting factor for the normalized renal biomarkers. In case a ¼ 1, the FAS equation depends entirely on Scr/Q crea and equals the FAS crea equation; in case a ¼ 0, the FAS equation becomes the ScysC-based FAS cysC equation. In all other situations for 0 < a < 1, the equation is a combined Scr/ScysC equation. For a ¼ 0.5, the denominator is equal to the average of both normalized biomarkers. We further discuss the influence of a in the 'Results' section.
mGFR, Scr and cystatin C assays. A summary of the methods used in the different collaborating centres is given in Tables  1 and 2 . Direct GFR measurements were obtained with different reference methods as described previously [2, 10] . Scr was measured with an enzymatic assay, equivalent to IDMS, or directly with IDMS, or recalculated to the enzymatic assay, in all centres. ScysC was measured with the calibrated particleenhanced nephelometric (PENIA) method of Siemens in SaintEtienne, Berlin and partially in Lyon. The ScysC measurements for the CRIC Study were done with the non-calibrated PENIA assay of Siemens, but calculated back to the certified reference material, as previously described [4] . The non-calibrated PENIA assay of Siemens was also used in Rochester, Kent, and partially in Lyon, and the results were recalculated to the certified reference standard, using the multiplication factor in Rochester [11] and in Lyon and Kent [12] , according to the manufacturer's specifications. Tromsø used the non-calibrated (with back calculation) and Leuven used the calibrated particleenhanced turbidimetric (PETIA, Tina quantV R ) assay of Roche (Tables 1 and 2 ).
eGFR equations. The new FAS cysC equation and the FAS combi equation were compared and validated against mGFR and against the currently available and recommended eGFR equations listed in Table 3 .
Statistical analysis. The performance statistics are presented as constant bias (mean of eGFR-mGFR) and proportional bias (mean of eGFR/mGFR), root mean square error (RMSE) of prediction, Lin's concordance correlation coefficient (Lin's CCC, which is a measure of both correlation and agreement as it evaluates the degree to which pairs of observations fall on the identity line), P10 and P30 (the percentage of subjects within 10% and 30% of mGFR), for the different age groups, total and in subgroups according to mGFR <60 and !60 mL/min/1.73 m 2 . McNemar's test is used to compare P30 among equations.
R E S U L T S
Description of the cohorts
Summary statistics for the patient characteristics of the 11 cohorts are given in Tables 4 and 5 , and are described in Supplementary data.
Rationale for Q cysC values for ScysC
To define normalization factors for ScysC we searched the literature for normal reference ranges and we investigated whether these ranges depend on age or gender differences. We realized that the literature before the year 2010 was based on non-standardized cystatin C assays, but, in general, ScysC is independent of age (up to age 70 years) and gender in children, adolescents and adults [14] [15] [16] , although there might be small
differences between sexes and races [17] . We used the value of 0.82 mg/L as the normalization factor, as it is the middle of the normal reference interval for children, adolescents and adults up to $70 years (and in line with the manufacturer's information on reference ranges) [8, 18] . The ScysC-based CKD-EPI equation normalized ScysC by 0.80 for both males and females [4] , a value that is close to the proposed value of 0.82 in this study. The new CAPA equation does not have a gender factor in the equation, suggesting that the same Q cysC normalization constant can be used for both sexes [7] . For older adults, we could not find normal reference ranges in the literature. In our dataset of 1333 apparently healthy older persons aged >70 years from the Berlin Initiative Study, we modelled Q cysC as a linear function of age: Figure 1 ). At the age of 67.5 years, the corresponding value of Q cysC ¼ 0.82. [4] eGFR
Age Â (0.969 if female) (j ¼ 0.7 for females, 0.9 for males, a ¼ À0.248 for females and À0.207 for males) BIS2 [8] eGFR 
Performance results of the different equations
The performance statistics for the three FAS equations for the different age groups are presented in Tables 6-8. The 
F u l l -a g e -s p e c t r u m c y s t a t i n C -b a s e d e G F R e q u a t i o n Tables 6-8 are presented for all subjects within each age group, but also for subgroups according to the mGFR threshold of 60 mL/min/1.73 m 2 . For children, the FAS cysC equation performs significantly better than the FAS crea equation based on Q crea (age) and slightly better than or, in some cases, equivalent to the FAS crea equation based on Q crea (height) ( Table 6 ). We found that n ¼ 7 children [for Q crea (height)] and n ¼ 20 children [for Q crea (age)] with Scr/Q crea <0.67 had FAS crea predictions that largely overestimate mGFR and were responsible for the large bias, RMSE and worse performance statistics. These children had spina bifida, Duchenne muscular dystrophy and severe growth retardation, explaining the very low Scr values and the poor match between Q crea and age. The FAS cysC equation has equivalent Lin's CCC with CAPA but better RMSE. Also, P10 and P30 performance statistics were superior to CAPA. The Schwartz cysC equation shows the best performance in the mGFR <60 mL/min/1.73 m 2 subgroup. However, although all children suffered from some underlying renal pathology, this subgroup was rather small (n ¼ 57, 15%). The FAS combi equations [based on Q crea (age) and Q crea (height)] outperform all other paediatric equations and increase the precision for P10 to %45% and P30 to %90%, which is significantly higher (P < 0.0001) compared with single biomarker equations, including the single biomarker FAS equations.
For adults, the FAS cysC equation performs worse than FAS crea , but better (overall and in the mGFR !60 mL/min/1.73 m 2 subgroup) or equivalent (in the mGFR <60 mL/min/1.73 m 2 subgroup) than the CKD-EPI cysC equation. The FAS cysC equation is significantly better than the CAPA equation. The combined equations show higher precision, but the difference with the FAS crea equation is small. However, the FAS combi equation is overall the best prediction equation and performs better than the CKD-EPI combined equation, except for mGFR <60 mL/min/1.73 m 2 , where the performance is statistically equivalent.
In older adults, the FAS cysC equation (with Q cysC ¼ 0.95) performs better than the CKD-EPI cysC equation and shows equivalent performance with the FAS crea equation. If we use the linear function Q cysC ¼ 0.863 þ 0.01704 Â (Age -70) to normalize ScysC in the FAS cysC and FAS combi equations, then the performance results (data not shown) are not significantly different than when Q cysC ¼ 0.95 is used to normalize ScysC in the FAS equation. The combined FAS equation is performing equivalent to the BIS2 equation, reaching P10 > 50% and P30 > 90%, and better than the combined CKD-EPI equation.
In Tables 6-8 , we highlighted (the equations marked with asterisk) the best performing equation per biomarker category based on the scoring system previously used by Hoste et al. [13] , which is based on bias, P10 and P30. We also highlighted (in bold) the best performance statistic. We also calculated the performance statistics (RMSE in Figure 2 and P30 in Figure 3 
D I S C U S S I O N
Through the introduction of the international certified reference material ERM-DA471/IFCC for cystatin C [5] it has become possible to develop ScysC-based as well as combined Scr-/ScysC-based eGFR equations on the basis of normalized biomarkers. Despite the fact that manufacturers still need to improve the accuracy of cystatin C assays [19] , we have shown here that the basic concept upon which the FAS crea equation was built [2] is not only applicable for normalized Scr, but can also be applied to normalized ScysC. By replacing normalized Scr with ScysC, or introducing the (weighted) average of both biomarkers, we can change from a Scr-based FAS equation to a ScysC-based FAS equation or a combined Scr-/ScysC-based FAS equation. These FAS equations show performance values that are equivalent or in some conditions superior to the currently recommended eGFR equations for children, adolescents, adults and older adults. Normalization of the biomarkers is a key in this construction. In the case of Scr, normalization is required to account for the difference in creatinine generation during childhood, the age/gender differences during adolescence and the difference between adult men and women. Normalization of ScysC is required to account for the age effect beyond the age of 70 years. For the healthy population, the normalized biomarkers show equivalent distributions with mean of '1' and 2.5th and 97.5th Pct of 0.67 and 1.33, respectively. These similar characteristics of normalized biomarker concentration distributions lead to an interchangeable usage of both renal markers in the FAS equation(s).
The performance of the new FAS cysC equation was better than the CAPA equation and better (in adults with mGFR !60 mL/min/1.73 m 2 and in older adults) or equivalent (in adults with mGFR <60 mL/min/1.73 m 2 ) to the CKD-EPI cysC equation. In children, the RMSE statistic is worst (highest) for the FAS crea equation due to a fraction of children with Scr/ Q crea <0.67. Therefore, we would recommend not to use FAS crea (or the combined FAS equations) when Scr/Q crea <0.67 [2] . For adults, based on the performance statistics (RMSE and P30), there is still a slight preference for the single biomarker FAS crea equation over the single biomarker FAS cysC equation. For older adults, both single biomarker FAS equations perform in a similar manner. However, for all age groups, the FAS combi equation with a % 0.5 (corresponding to the average of both biomarkers) showed the smallest RMSE and the highest P30 and P10. Also the FAS combi equation outperformed all other combined equations, with the exception of the BIS2 equation, which showed an equivalent performance for older adults (but note that BIS data used to derive the BIS equations are part of the current validation dataset) and the CKD-EPI equation for adults with mGFR <60 mL/min/1.73 m 2 , where FAS showed equivalent performance results.
When the overall performance statistics for specific age groups was calculated, we found that a % 0.5 corresponding to the average of normalized creatinine and cystatin C biomarker concentrations gave the best performance statistics for all age groups and demonstrated the smallest RMSE and highest P10 and P30 values. Although we calculated the average of both biomarkers and entered this into the FAS equation, it approximated the average of both single biomarker FAS equations (Scr and ScysC), a finding that has been observed by Björk et al. [20, 21] in a Swedish cohort, when combining the Scr-based LundMalmö and the ScysC-based CAPA equation. The choice to use a single or the mean of two biomarkers should be based on the clinical context, when conditions are disclosed that invalidate either Scr or ScysC as renal biomarker. The use of Scr may be discouraged in case of severe muscle wasting (anorexic patients, patients with muscle disorder, like Duchenne muscle dystrophy), immobile patients, or elderly cachectic patients with reduced muscle mass. Also, abnormal meat consumption, abnormal muscle development in athletes or weight lifters, or medication usage that affects creatinine generation may have an impact on the validity of creatinine as a renal biomarker. The use of ScysC-based equations may be discouraged when patients are treated with (high dose) glucocorticoids or other medication impacting on the biomarker's serum concentration [22] , in obese patients, tobacco users or patients with thyroid dysfunction or inflammation [11, [23] [24] [25] . The combination of both biomarkers has the advantage that it may cancel out the non-GFRrelated factors influencing creatinine and cystatin C in different directions compared with mGFR [24] [25] [26] . The great advantage of our approach is that the same equation can be used, only the appropriate normalized biomarker has to be chosen (either Scr/Q crea , or ScysC/Q cysC or the average of both). However, the cost of cystatin C is relatively high and additional studies are needed to prove that measuring cystatin C is cost-effective. In the context of GFR estimation, the additional value of cystatin C could be defined by the clinical condition, knowing that non-GFR determinants influence both creatinine and cystatin C. We also investigated the impact of the weighting factor a on the performance of the FAS equations by varying a (between 0 ¼ FAS cysC and 1 ¼ FAS crea ) and calculating the difference 'FAS -mGFR', on an individual basis. Due to the way the FAS equations are designed, FAS crea % FAS cysC % FAS combi , in the case of the normalized biomarkers Scr/Q crea % ScysC/Q cysC . When Scr/Q crea strongly deviates from ScysC/Q cysC , then FAS crea will strongly deviate from FAS cysc and FAS combi will lie in-between both single biomarker FAS predictions. We found that, on an individual basis, in approximately one-third of the subjects, the FAS crea equation was closest to mGFR, in onethird of the subjects the FAS cysC equation had the lowest individual bias and in one-third the FAS combi equation was the best choice for a specific value of a. In the latter, when mGFR lies between FAS crea and FAS cysC predictions, there is always a value of a for which FAS combi ¼ mGFR. We realize that this analysis is mainly speculative as we do not know the optimal value of a in actual clinical situations, but the intention of this analysis was to evaluate in which conditions a preference for single biomarker FAS predictions or for the combined biomarker FAS prediction might exist. Unfortunately, we could not identify specific conditions where one over the other equations was to be preferred (unless the situation where Scr/Q crea <0.67).
The strength of this study is the large number of subjects (n ¼ 6132) covering the complete age span from 2 to 100 years of age. This study partially used data from our previous study, where n ¼ 6870 subjects were used to validate the FAS crea equation. Although both studies partially used the same subjects, the ScysC data was not part of the previous evaluation. All ScysC concentrations were analysed with cystatin C assays based on the international certified standard or were back-calculated using calibration curves developed for that purpose. The reference tests used in this study comprise all currently used direct measurement methods: 51 Cr-EDTA (plasma/renal clearance), inulin (renal clearance), iohexol (plasma clearance in its different configurations) and iothalamate (renal clearance), illustrating the diversity of mGFR results and demonstrating the robustness of the FAS construction. Moreover, the cohorts used in this study were from different countries in Europe (Norway, Germany, France, Belgium) and the USA (Rochester, MN and the CRIC cohort), making the sample representative for the general Caucasian population and kidney disease population.
Our study has some limitations. First, we did not incorporate different ancestries, and, therefore, this validation study is limited to Caucasians only. Although it is known that creatinine generation (and thus Scr) is affected by ancestry, it is also known that ScysC is not influenced by differences in ancestry. We always have claimed that using appropriate ancestry-specific normalization factors for Scr may solve this problem and consequently the FAS concept remains applicable. Secondly, our goal was to validate the new FAS equations against mGFR and compare them with the existing and recommended equations, not to predict the risk of mortality. Whether the FAS equations are better predictors of mortality is another topic and requires further studies using a different statistical methodology [27] .
C O N C L U S I O N S
The fundamental concept for the Scr-based FAS equation development, namely that mean GFR for healthy subjects evolves along an age-specific curve, and that deviation from that curve is related to the inverse of normalized Scr/Q crea , also holds true for normalized ScysC/Q cysC . The current work shows that the FAS equations display better or equivalent prediction performance than the currently recommended eGFR equations, across the full age spectrum, both in normal and reduced kidney function. The FAS equation is not only applicable to all ages, but also to all currently recommended renal biomarkers. The FAS concept may also be applicable to other renal biomarkers, if appropriately normalized, but this remains to be proven once standardized assays are in place.
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